Shares of Elevance Health (ELV), which fell 11.5% during Wednesday trading following the warning and guidance retraction from peer Centene (CNC), are up 1% to $354.00 in after-hours trading after Elevance announced it will release second quarter results on July 17 at 6:00 a.m. Eastern Daylight Time. Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning, the company noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- ‘Time to Sell Centene Stock (CNC)?’ as Analysts Downgrade Rating on Guidance Pull
- Morning Movers: Tesla higher following Q2 delivery figures
- JPMorgan says too early to conclude other MCOs exposed to same risk as Centene
- Centene price target lowered to $52 from $65 at BofA
- Wells says OBBBA incrementally positive for managed care, uncertainty still high